16,792 Shares in HUTCHMED (China) Limited (NASDAQ:HCM) Purchased by Crossmark Global Holdings Inc.

Crossmark Global Holdings Inc. bought a new stake in shares of HUTCHMED (China) Limited (NASDAQ:HCM) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 16,792 shares of the company’s stock, valued at approximately $328,000.

A number of other large investors also recently made changes to their positions in HCM. Blue Trust Inc. boosted its position in HUTCHMED by 638.2% during the third quarter. Blue Trust Inc. now owns 3,536 shares of the company’s stock valued at $69,000 after purchasing an additional 3,057 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in shares of HUTCHMED by 63.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,966 shares of the company’s stock valued at $117,000 after buying an additional 2,321 shares during the last quarter. Rhumbline Advisers grew its stake in shares of HUTCHMED by 8.1% in the 2nd quarter. Rhumbline Advisers now owns 7,553 shares of the company’s stock valued at $129,000 after buying an additional 564 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new position in HUTCHMED in the second quarter worth approximately $213,000. Finally, Vanguard Personalized Indexing Management LLC raised its position in HUTCHMED by 9.7% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 13,216 shares of the company’s stock valued at $226,000 after acquiring an additional 1,168 shares in the last quarter. Institutional investors and hedge funds own 8.82% of the company’s stock.

HUTCHMED Stock Performance

Shares of HUTCHMED stock opened at $16.74 on Monday. HUTCHMED has a 12-month low of $11.93 and a 12-month high of $21.92. The company has a quick ratio of 2.68, a current ratio of 2.81 and a debt-to-equity ratio of 0.07. The stock has a 50 day moving average price of $18.71 and a two-hundred day moving average price of $18.65.

Analyst Ratings Changes

Several analysts have commented on HCM shares. StockNews.com raised shares of HUTCHMED from a “hold” rating to a “buy” rating in a research report on Monday, November 4th. The Goldman Sachs Group increased their target price on shares of HUTCHMED from $17.00 to $19.00 and gave the stock a “neutral” rating in a research report on Thursday, August 1st.

HUTCHMED Profile

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors.